The Experts below are selected from a list of 324399 Experts worldwide ranked by ideXlab platform
Tsai-wang Huang - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer
European Radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. Results We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 ( p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). Conclusions SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. Key Points • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
European radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 (p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
Lowri H Phylip - One of the best experts on this subject based on the ideXlab platform.
-
N-terminal extension of the yeast Ia3 aspartic proteinase inhibitor relaxes the strict intrinsic selectivity.
The FEBS journal, 2007Co-Authors: Timothy John Winterburn, David Wyatt, Lowri H Phylip, Colin Berry, Daniel Bur, John KayAbstract:Yeast Ia3 aspartic proteinase inhibitor operates through an unprecedented mechanism and exhibits a remarkable specificity for one target enzyme, saccharopepsin. Even aspartic proteinases that are very closely similar to saccharopepsin (e.g. the vacuolar enzyme from Pichia pastoris) are not susceptible to significant inhibition. The Pichia proteinase was selected as the target for initial attempts to engineer Ia3 to re-design the specificity. The Ia3 polypeptides from Saccharomyces cerevisiae and Saccharomyces castellii differ considerably in sequence. Alterations made by deletion or exchange of the residues in the C-terminal segment of these polypeptides had only minor effects. By contrast, extension of each of these wild-type and chimaeric polypeptides at its N-terminus by an MK(H)7MQ sequence generated inhibitors that displayed subnanomolar potency towards the Pichia enzyme. This gain-in-function was completely reversed upon removal of the extension sequence by exopeptidase trimming. Capture of the potentially positively charged aromatic histidine residues of the extension by remote, negatively charged side-chains, which were identified in the Pichia enzyme by modelling, may increase the local Ia3 concentration and create an anchor that enables the N-terminal segment residues to be harboured in closer proximity to the enzyme active site, thus promoting their interaction. In saccharopepsin, some of the counterpart residues are different and, consistent with this, the N-terminal extension of each Ia3 polypeptide was without major effect on the potency of interaction with saccharopepsin. In this way, it is possible to convert Ia3 polypeptides that display little affinity for the Pichia enzyme into potent inhibitors of this proteinase and thus broaden the target selectivity of this remarkable small protein.
-
key features determining the specificity of aspartic proteinase inhibition by the helix forming Ia3 polypeptide
Journal of Biological Chemistry, 2007Co-Authors: Timothy John Winterburn, David Wyatt, Lowri H Phylip, Rebecca Harrison, Colin BerryAbstract:The 68-residue Ia3 polypeptide from Saccharomyces cerevisiae is essentially unstructured. It inhibits its target aspartic proteinase through an unprecedented mechanism whereby residues 2–32 of the polypeptide adopt an amphipathic -helical conformation upon contact with the active site of the enzyme. This potent inhibitor (Ki < 0.1 nM) appears to be specific for a single target proteinase, saccharopepsin. Mutagenesis of Ia3 from S. cerevisiae and its ortholog from Saccharomyces castellii was coupled with quantitation of the interaction for each mutant polypeptide with saccharopepsin and closely related aspartic proteinases from Pichia pastoris and Aspergillus fumigatus. This identified the charged K18/D22 residues on the otherwise hydrophobic face of the amphipathic helix as key selectivity-determining residues within the inhibitor and implicated certain residues within saccharopepsin as being potentially crucial. Mutation of these amino acids established Ala-213 as the dominant specificity-governing feature in the proteinase. The side chain of Ala-213 in conjunction with valine 26 of the inhibitor marshals Tyr-189 of the enzyme precisely into a position in which its side-chain hydroxyl is interconnected via a series of water-mediated contacts to the key K18/D22 residues of the inhibitor. This extensive hydrogen bond network also connects K18/D22 directly to the catalytic Asp-32 and Tyr-75 residues of the enzyme, thus deadlocking the inhibitor in position. In most other aspartic proteinases, the amino acid at position 213 is a larger hydrophobic residue that prohibits this precise juxtaposition of residues and eliminates these enzymes as targets of Ia3. The exquisite specificity exhibited by this inhibitor in its interaction with its cognate folding partner proteinase can thus be readily explained.
-
adaptation of the behaviour of an aspartic proteinase inhibitor by relocation of a lysine residue by one helical turn
Biological Chemistry, 2006Co-Authors: Tim J Winterburn, David Wyatt, Lowri H Phylip, Colin BerryAbstract:In addition to self-inhibition of aspartic proteinase zymogens by their intrinsic proparts, the activity of certain members of this enzyme family can be modulated through active-site occupation by extrinsic polypeptides such as the small Ia3 protein from Saccharomyces cerevisiae. The unprecedented mechanism by which Ia3 helicates to inhibit its sole target aspartic proteinase locates an i, i+4 pair of charged residues (Lys18+Asp22) on an otherwise-hydrophobic face of the amphipathic helix. The nature of these residues is not crucial for effective inhibition, but re-location of the lysine residue by one turn (+4 residues) in the helical Ia3 positions its side chain in the mutant Ia3-proteinase complex in an orientation essentially identical to that of the key lysine residue in zymogen proparts. The binding of the extrinsic mutant Ia3 shows pH dependence reminiscent of that required for the release of intrinsic zymogen proparts so that activation can occur.
-
Ia3 an aspartic proteinase inhibitor from saccharomyces cerevisiae is intrinsically unstructured in solution
Biochemistry, 2004Co-Authors: Terry B Green, Omjoy K Ganesh, Stephen J Hagen, Lowri H Phylip, Ben M Dunn, Kyle Perry, Leif Smith, Timothy M Logan, Arthur S. EdisonAbstract:Ia3 is a highly specific and potent 68-amino acid endogenous inhibitor of yeast proteinase A (YprA), and X-ray crystallographic studies have shown that Ia3 binds to YprA as an α-helix [Li, M., Phylip, L. H., Lees, W. E., Winther, J. R., Dunn, B. M., Wlodawer, A., Kay, J., and Gustchina, A. (2000) Nat. Struct. Biol. 7, 113−117]. Surprisingly, only residues 2−32 of Ia3 are seen in the X-ray structure, and the remaining residues are believed to be disordered in the complex. We have used circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy to show that Ia3 is unstructured in the absence of YprA. Specifically, Ia3 produced a CD spectrum characteristic of an unstructured peptide, and the 15N HSQC NMR spectra of Ia3 were characteristic of a polypeptide lacking intrinsic structure. We characterized the unstructured state of Ia3 by using singular-value decomposition (SVD) to analyze the CD data in the presence of TFE, by fully assigning the unbound Ia3 protein by NMR and comparing the chemical...
-
Ia3, an aspartic proteinase inhibitor from Saccharomyces cerevisiae, is intrinsically unstructured in solution.
Biochemistry, 2004Co-Authors: Terry B Green, Omjoy K Ganesh, Stephen J Hagen, Lowri H Phylip, Ben M Dunn, Kyle Perry, Leif Smith, Timothy M Logan, Arthur S. EdisonAbstract:Ia3 is a highly specific and potent 68-amino acid endogenous inhibitor of yeast proteinase A (YprA), and X-ray crystallographic studies have shown that Ia3 binds to YprA as an α-helix [Li, M., Phyl...
Hsiu-ping Chou - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer
European Radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. Results We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 ( p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). Conclusions SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. Key Points • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
European radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 (p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
Shih-chun Lee - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer
European Radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. Results We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 ( p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). Conclusions SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. Key Points • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
European radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 (p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
Hung Chang - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer
European Radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. Results We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 ( p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). Conclusions SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. Key Points • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
-
Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
European radiology, 2021Co-Authors: Hsiu-ping Chou, Kuan-hsun Lin, Hsu-kai Huang, Li-fan Lin, Ying-yi Chen, Shih-chun Lee, Hung Chang, Tsai-wang HuangAbstract:To investigate the role of PET in predicting the prognosis of resected stage IA non-small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. We retrospectively reviewed the data of patients who underwent surgical resection for lung cancer between January 2004 and December 2014. The clinical data, imaging characteristics of nodules, surgical approaches, and outcomes were analyzed. We evaluated 998 cases; 637 patients with pathological stage I disease were categorized as follows: stage IA1 (251 cases), stage IA2 (250 cases), and stage Ia3 (136 cases). The mean follow-up period was 109 months. Significant differences were observed in sex, tumor differentiation, epidermal growth factor receptor mutation, smoking habits, lymphovascular space invasion, tumor size, maximum standard uptake value (SUVmax), and carcinoembryonic antigen level among the groups. Multivariable Cox regression revealed that ground-glass opacity ratio (hazard ratio (HR) = 0.001) and tumor SUVmax independently predicted the postoperative risk of relapse for stage Ia3 NSCLC. The HR for SUVmax > 4 was 8.986 (p < 0.001). The 5-year overall survival (OS) rates were 87.2%, 92.9%, and 82.7%, and the 5-year disease-free survival (DFS) rates were 93.2%, 84.2%, and 70.51% for stage IA1, IA2, and Ia3 NSCLC, respectively (both p < 0.001). OS and DFS rates were poor in stage Ia3 NSCLC patients with an SUVmax uptake > 4 (OS, 71.0% and 92.2%; DFS, 50.2% and 87.3%, for SUVmax > 4 and ≤ 4, respectively; both p = 0.001). SUVmax was a prognostic factor for resected stage IA NSCLC. Postoperative treatment may be considered for Ia3 NSCLC with SUVmax > 4. • PET helps surgeons to assess patients with early-stage lung cancer. • This retrospective study revealed that PET plays an influential role in predicting the prognosis of resected lung cancer. • Better prognostication aids better planning of therapeutic strategies with diversification.
